Certain information has bee excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENTLicense Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances)
Whereas the Licensed Technology (as defined below) was made in the course of research at the Licensor (or an affiliated research institution or hospital) by the Principal Investigator(s) (as defined below).
Certain information has been excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND...Investors’ Rights Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Texas
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 2nd day of July, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Certain information has been excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. RESEARCH,...License Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Texas
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of November 19, 2019 (the “Effective Date”) by and between The Board of Regents of the University of Texas System (“System”), an agency of the State of Texas, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System (“Licensor”), and Taysha Gene Therapies, Inc. a corporation organized under the laws of the state of Texas (“Licensee”). Licensor and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
Certain information has been excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT TO...License Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances)
This Amendment to the November 19, 2019 Research, Collaboration & License Agreement (“Amendment”) is entered into as of April 2, 2020 (the “Amendment Effective Date”) by and between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System (“Licensor”), and Taysha Gene Therapies, Inc., a Texas corporation (“Licensee”). Licensor and Licensee are referred to collectively as the “Parties” and individually as a “Party”. All capitalized terms used but not defined herein shall have the meaning ascribed to such term in the Agreement.
LICENSE AGREEMENT DATED AS OF AUGUST 14, 2020 BY AND BETWEEN ABEONA THERAPEUTICS, INC. AND TAYSHA GENE THERAPIES, INC.License Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (this “Agreement”) is dated as of August 14, 2020 (the “Effective Date”) by and between Abeona Therapeutics Inc., a Delaware corporation having its principal place of business at 1330 Avenue of the Americas, Suite 33A, New York, NY 10019 (“Licensor”), and Taysha Gene Therapies, Inc., a Delaware corporation having a place of business at 2280 Inwood Road, Dallas, TX 75325 (“Company”). Licensor and Company may be referred to herein as a “Party” or, collectively, as “Parties”.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Texas
THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is signed and effective as of April 1, 2020 (the “Effective Date”), by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and R.A. Session II, an individual (the “Executive”).
